30 Day Trial

Alphatec Secures Additional $30MM Funding

Share:

Squadron Capital committed to provide an additional US $30MM in secured debt financing to Alphatec, beyond the $35 million provided in 4Q18. Proceeds will support the company as it seeks to scale up to $200MM in annual revenue by 2022.

Thus far in 2019, Alphatec has announced FDA 510(k) clearance to market automated SafeOp neuromonitoring for real-time intra-op nerve location, and launched the IdentiTi-C Porous Titanium Interbody for anterior cervical discectomy and fusion. The latter is the first of six IdentiTi titanium systems that the company intends to introduce this year.

Squadron Capital serves the orthopedic industry with capital and manufacturing resources in four plants located in Alabama, Connecticut, Florida and North Carolina, offering a “hybrid” support model of integrated product financing and manufacturing to OEM customers.

Source: Squadron Capital